8-K: Moleculin Accelerates AML Trial Recruitment

Moleculin Biotech announced accelerated recruitment and global expansion for its pivotal Phase 3 MIRACLE clinical trial of Annamycin for relapsed or refractory acute myeloid leukemia.

Summary

• Updates on active site status and recruitment for the pivotal Phase 2B/3 MIRACLE trial of Annamycin in combination with cytarabine (AnnAraC) for adult patients with relapsed or refractory acute myeloid leukemia (R/R AML).
• The MIRACLE trial is a global approval trial with sites in the US, Europe, and the Middle East.
• Currently, 13 subjects have been recruited (treated, enrolled, or screened).
• Forecasts total recruitment of 20 or more subjects by the end of September 2025.
• On track to recruit 45 patients in Q4 2025 for initial data unblinding.
• Global expansion includes Spain, Georgia, Poland, Romania, Italy, Lithuania, and the US, in addition to Ukraine.
• Adding 8 new active sites by the end of September 2025, increasing the total to 20 recruiting sites.
• Expects to increase to over 30 active sites by year-end.
• Part A of the trial (75 to 90 subjects) is expected to conclude in the first half of 2026.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA for R/R AML and soft tissue sarcoma, and Orphan Drug Designation from the EMA for R/R AML.
• Annamycin benefits from composition of matter patent protection through 2040, with potential extension to 2045.

Sentiment

Score: 8

Explanation: The announcement details significant acceleration in a pivotal clinical trial, global expansion, and positive recruitment momentum, which are strong indicators of progress. The early data unblinding provides advantageous visibility. The primary caveat is the explicit mention of needing significant additional financing without commitments, which introduces a notable risk.

Positives

• Accelerated recruitment in the pivotal Phase 3 MIRACLE trial, with 13 subjects already screened/enrolled/treated and a forecast of 20+ by end of September 2025.
• Global expansion of recruiting sites to include Spain, Georgia, Poland, Romania, Italy, Lithuania, and the US, beyond Ukraine.
• Increase in active sites, with 8 new sites by end of September 2025, totaling 20, and over 30 by year-end.
• On track to recruit 45 patients in Q4 2025 for initial data unblinding, providing early insights into efficacy and safety.
• High investigator eagerness to enroll patients in the MIRACLE trial.
• Operational efficiency demonstrated by screening 13 subjects in just over a year since the end of Phase 2 meeting with the FDA, with 10 already dosed.
• Expectation to conclude Part A of the trial (75-90 subjects) in the first half of 2026, providing a second data unblinding.
• Annamycin holds Fast Track Status and Orphan Drug Designation from the FDA and Orphan Drug Designation from the EMA for R/R AML.
• Composition of matter patent protection for Annamycin through 2040, with potential extension to 2045.

Risks

• Moleculin will require significant additional financing to conduct its clinical trials as described, for which the Company has no commitments.
• The milestones described assume the Company's ability to secure such financing on a timely basis.
• Expectations reflected in forward-looking statements may prove to be materially different from actual results.
• The MIRACLE study is subject to appropriate future filings with and potential additional feedback from the FDA and their foreign equivalents.
• Clinical trial approval with EMA was granted under the condition that the Company present results of appropriate nonclinical GLP studies before initiating the Phase 3 portion (Part B) of the study.

Future Outlook

The company expects to recruit 20 or more subjects by the end of September 2025 and 45 patients in Q4 2025 for initial data unblinding. They anticipate increasing to over 30 active sites by year-end and concluding Part A of the trial (75-90 subjects) in the first half of 2026, leading to a second data unblinding. Part B of the trial will commence after Part A, randomizing approximately 220 additional subjects.

Management Comments

• "Our team is diligently expanding our active site footprint across the US, EU, and neighboring regions."
• "We are confident in our target to recruit the 45th subject by Q4 2025 and achieve our first data unblinding shortly thereafter, especially since the consistent message we are receiving from investigators is that they are very eager to enroll patients in the MIRACLE trial."
• "Moving from our end of Phase 2 meeting with the FDA to screening 13 subjects in just over a year exemplifies our operational efficiency."
• "Of these 13, 10 have been dosed, further supporting our confidence in the speed of recruitment for MIRACLE."
• "We expect to increase to over 30 active sites by year-end, as we move toward a second data unblinding for the conclusion of Part A of the trial."
• "That will only require an additional 30 to 45 subjects, so we expect to conclude Part A in the first half of 2026, before commencing Part B of the trial."
• "This level of early visibility is, we believe, exceptionally rare for a Phase 2B/3 trial and highly advantageous for investors."

Industry Context

The development of Annamycin for R/R AML addresses a critical unmet medical need in oncology, as AML remains a challenging cancer, particularly for patients who relapse or are refractory to initial induction therapy. The adaptive design of the Phase 2B/3 trial and the focus on avoiding multidrug resistance and cardiotoxicity (common issues with existing anthracyclines) position Annamycin as a potentially differentiated treatment in a competitive therapeutic landscape. The FDA's Project Optimus initiative, mentioned in relation to dose selection, reflects a broader industry trend towards optimizing drug development for safety and efficacy.

Comparison to Industry Standards

• Annamycin is designed to avoid multidrug resistance mechanisms and lack the cardiotoxicity common with currently prescribed anthracyclines, which is a significant advantage over existing treatments like doxorubicin or daunorubicin.
• The adaptive design of the Phase 2B/3 MIRACLE trial, allowing for early unblinding at 45 subjects and again at 75-90 subjects, provides a level of early visibility that management believes is "exceptionally rare for a Phase 2B/3 trial" and highly advantageous for investors, potentially accelerating development compared to traditional linear trial designs.
• The company's operational efficiency in screening 13 subjects in just over a year since the end of Phase 2 meeting with the FDA, with 10 dosed, indicates a relatively swift progression for a complex global oncology trial.

Stakeholder Impact

• Shareholders/Investors: Potential for increased value due to accelerated trial progress and early data insights, but also risk from the need for significant additional financing. Early visibility is deemed "highly advantageous for investors."
• Patients (R/R AML): Potential for a new, more effective, and less cardiotoxic treatment option if Annamycin proves successful.
• Healthcare Providers/Investigators: Eagerness to enroll patients suggests a perceived need for new treatments and confidence in the trial.
• Employees: Positive operational momentum and expansion could indicate job security and growth opportunities.

Next Steps

• Recruit 20 or more subjects by the end of September 2025.
• Add 8 new active sites by the end of September 2025, increasing the total to 20.
• Recruit the 45th subject in Q4 2025 for the first unblinding of preliminary data assessment regarding efficacy and safety.
• Increase to over 30 active sites by year-end.
• Conclude Part A of the trial (75-90 subjects) in the first half of 2026 for a second data unblinding.
• Submit results of appropriate nonclinical GLP studies as a substantial modification to the existing approved CTA for EMA approval before initiating Part B of the study.
• Commence Part B of the trial, randomizing approximately 220 additional subjects.

Key Dates

Recommendation

The accelerated recruitment and global expansion of the pivotal Phase 3 MIRACLE trial for Annamycin are significant positive developments, indicating strong operational execution and potential for earlier data readouts. The drug's Fast Track and Orphan Drug designations, along with patent protection, add to its long-term potential. However, the explicit disclosure of a need for "significant additional financing" without current commitments introduces a material financial risk. While the clinical progress is encouraging, the uncertainty surrounding future funding warrants a cautious "hold" recommendation until more clarity on the financing strategy is provided. Investors should monitor the company's ability to secure the necessary capital to sustain the trial's momentum.

Keywords

Moleculin Biotech, MBRX, Annamycin, Acute Myeloid Leukemia, AML, MIRACLE trial, Phase 3, Clinical Trial, Oncology, Biotechnology, Drug Development, Relapsed Refractory AML, AnnAraC, Cytarabine